Figures & data
Table 1 Baseline demographics and clinical characteristics (efficacy analysis set)
Figure 1 Patient disposition.
Figure 2 COPD severity as per GOLD classification based on (A) airflow limitation and (B) GOLD groups (efficacy analysis set).
Figure 3 Distribution of patients according to (A) CAT scores and (B) mMRC scores (efficacy analysis set).
Abbreviations: CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; mMRC, modified Medical Research Council.
Figure 4 Proportion of patients experiencing exacerbations (efficacy analysis set).
Abbreviation: COPD, chronic obstructive pulmonary disease.
Figure S1 Treatment patterns over 12 months (efficacy analysis set).
Note: Data are presented as percentage of patients.
Abbreviations: FDC, fixed-dose combination; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; PDE-4, phosphodiesterase-4; SABA, short-acting β2-agonists; SAMA, short-acting muscarinic antagonists.
Figure S2 Long-acting inhaled therapy and agreement of treatment with GOLD guidelines (A and B) at baseline; (C and D) at 6 months; (E and F) at 12 months (efficacy analysis set).
Notes: Data are presented as number of patients (A, C, and E) and percentage of patients (B, D, and F). A: GOLD group A; B: GOLD group B; C: GOLD group C; D: GOLD group D.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Figure S3 Number of patients experiencing hospitalization (efficacy analysis set).
Table S1 List of study centers and contributors
Table S2 Adverse events and serious adverse events, according to system organ class